摘要
目的 研究Ki 67在乳腺癌中的表达与临床病理特征的关系.方法 应用免疫组织化学方法检测120例女性乳腺癌患者中Ki-67、ER、PR、C-erbB-2的表达,分析Ki-67与ER、PR 、C-erbB-2、肿瘤大小、淋巴结转移情况、年龄、月经状况、病理组织学分级等临床病理特征的关系.结果 120例患者乳腺癌组织中Ki-67表达(-)6例(5%);Ki-67表达(+)36例(30%);Ki-67表达(++)31例(25.83%);Ki-67表达(+++)47例(39.17%).Ki-67表达与乳腺癌组织中C-erbB-2表达、肿瘤大小、淋巴结转移情况、患者年龄、月经状况之间差异无统计学意义(P>0.05);与ER、PR受体表达、肿瘤组织学分级相关(P<0.05).结论 Ki-67不能作为评估乳腺癌预后和指导临床治疗的重要指标.
Objective To investigate the expressing of Ki-67 in breast cancer tissues and explore the relationship between it and the clinic pathology characteristics.Methods Immunohistochemical SP was used to investigate Ki-67,ER,PR,C-erbB-2 expression in 120 cases of female breast cancer.Analysis the relatiouship between Ki67 and ER,PR,C-erbB-2,tunor size,lymph node metastasis,patients age,menstruation state and clinic pathology characteristics.Results Six cases' Ki-67 expression in 120 eases of female patients with breast cancer tissue were (-) (5%),36 cases' ki-67 expression were (+) (30%),31 cases Ki-67 Expression were (+ +)(25.83%),37 cases' Ki-67 expression were (+ + +) 39.17%.The expression of ki-67 did not correlate with the expression of C-crbB-2,tumor size,lymph node metastasis,patients age and menstruation state(P >0.05).The expression of ki-67 correlate with hormone receptor status and histology pathology classification.Conclusion Ki-67 cannot serve as an important index of evaluating prognosis of breast cancer and to guide clinical treatment.
出处
《国际外科学杂志》
2013年第9期604-607,F0003,共5页
International Journal of Surgery